全文获取类型
收费全文 | 6971篇 |
免费 | 931篇 |
国内免费 | 117篇 |
专业分类
耳鼻咽喉 | 91篇 |
儿科学 | 61篇 |
妇产科学 | 449篇 |
基础医学 | 1321篇 |
口腔科学 | 94篇 |
临床医学 | 403篇 |
内科学 | 503篇 |
皮肤病学 | 217篇 |
神经病学 | 241篇 |
特种医学 | 71篇 |
外国民族医学 | 2篇 |
外科学 | 332篇 |
综合类 | 860篇 |
现状与发展 | 2篇 |
一般理论 | 1篇 |
预防医学 | 1269篇 |
眼科学 | 9篇 |
药学 | 328篇 |
3篇 | |
中国医学 | 68篇 |
肿瘤学 | 1694篇 |
出版年
2024年 | 5篇 |
2023年 | 125篇 |
2022年 | 130篇 |
2021年 | 313篇 |
2020年 | 341篇 |
2019年 | 328篇 |
2018年 | 342篇 |
2017年 | 336篇 |
2016年 | 366篇 |
2015年 | 384篇 |
2014年 | 538篇 |
2013年 | 534篇 |
2012年 | 452篇 |
2011年 | 631篇 |
2010年 | 535篇 |
2009年 | 438篇 |
2008年 | 309篇 |
2007年 | 304篇 |
2006年 | 301篇 |
2005年 | 210篇 |
2004年 | 160篇 |
2003年 | 124篇 |
2002年 | 115篇 |
2001年 | 106篇 |
2000年 | 71篇 |
1999年 | 55篇 |
1998年 | 54篇 |
1997年 | 69篇 |
1996年 | 46篇 |
1995年 | 54篇 |
1994年 | 48篇 |
1993年 | 31篇 |
1992年 | 35篇 |
1991年 | 35篇 |
1990年 | 29篇 |
1989年 | 25篇 |
1988年 | 9篇 |
1987年 | 10篇 |
1986年 | 5篇 |
1985年 | 5篇 |
1984年 | 5篇 |
1983年 | 3篇 |
1982年 | 1篇 |
1981年 | 1篇 |
1979年 | 1篇 |
排序方式: 共有8019条查询结果,搜索用时 335 毫秒
1.
2.
《Vaccine》2016,34(39):4724-4731
Human papillomavirus (HPV) infection is the most common sexually transmitted disease worldwide. HPVs are oncogenic small double-stranded DNA viruses that are the primary causal agent of cervical cancer and other types of cancers, including in the anus, oropharynx, vagina, vulva, and penis. Prophylactic vaccination against HPV is an attractive strategy for preventing cervical cancer and some other types of cancers. However, there are few safe and effective vaccines against HPV infections. Current first-generation commercial HPV vaccines are expensive to produce and deliver.The goal of this study was to develop an alternate potent HPV recombinant L1-based vaccines by producing HPV virus-like particles into a vaccine that is currently used worldwide. Live attenuated measles virus (MV) vaccines have a well-established safety and efficacy record, and recombinant MV (rMV) produced by reverse genetics may be useful for generating candidate HPV vaccines to meet the needs of the developing world.We studied in non-human primate rMV-vectored HPV vaccine in parallel with a classical alum adjuvant recombinant HPV16L1 and 18L1 protein vaccine produced in Pichia pastoris. A combined prime-boost approach using both vaccines was evaluated, as well as immune interference due to pre-existing immunity against the MV.The humoral immune response induced by the MV, Pichia-expressed vaccine, and their combination as priming and boosting approaches was found to elicit HPV16L1 and 18L1 specific total IgG and neutralizing antibody titres. Pre-existing antibodies against measles did not prevent the immune response against HPV16L1 and 18L1. 相似文献
3.
Nicole D. Facompre Pavithra Rajagopalan Varun Sahu Alexander T. Pearson Kathleen T. Montone Claire D. James Frederico O. Gleber-Netto Gregory S. Weinstein Jalal Jalaly Alexander Lin Anil K. Rustgi Hiroshi Nakagawa Joseph A. Califano Curtis R. Pickering Elizabeth A. White Bradford E. Windle Iain M. Morgan Roger B. Cohen Phyllis A. Gimotty Devraj Basu 《International journal of cancer. Journal international du cancer》2020,147(11):3236-3249
4.
Distinct genetic alterations and luminal molecular subtype in nested variant of urothelial carcinoma
5.
6.
Christos Loizou Göran Laurell Andreas Arvidsson David Lindquist Karin Nylander Katarina Olofsson 《Acta oto-laryngologica》2015,135(10):1058-1064
Conclusion: Recurrent respiratory papillomatosis (RRP) patients with high surgical treatment frequency (≥ 1/year, HF) were significantly younger and had a more widespread laryngeal disease compared to a low frequency treated group (< 1 treatment/year, LF). This study confirms the existence of a clinical RRP group, not primarily related to HPV sub-type, but more care-intensive and in need of more vigilant follow-up. Objectives: RRP is associated with high morbidity due to its influence on breathing and voice. The purpose of this study was to characterize RRP patients in northern Sweden and investigate possible predictor factors affecting therapeutic needs. Method: Patients from the regional referral area (northern Sweden) were categorized for age, disease duration, juvenile or adult onset, profile of disease development, number of surgical sessions in relation to disease duration, laryngeal deposition of papilloma, gender, and HPV sub-types, in order to identify patients with increased need for frequent surgical treatment. Results: The median age of the RRP patients (n = 48) was 44.5 years; 34 (71%) were males and 14 (29%) females, most were infected with HPV 6. Patients with high surgical treatment frequency/year were significantly younger and showed more widespread papillomatous vegetation in the larynx, compared to the low frequency treated group. 相似文献
7.
8.
The availability of human papillomavirus (HPV) vaccines and screening tests has raised the possibility of globally eliminating cervical cancer, which is caused by HPV. Cervical cancer is a very common malignancy worldwide, especially among deprived women. High vaccination coverage is key to the containment and eventual elimination of the infection. Public HPV vaccination programmes in Italy and Denmark were swiftly established and are among the most successful worldwide. Still, in both countries, it has been challenging to achieve and maintain the recommended coverage of > 80% in girls. In a well‐studied Italian region, vaccination coverage in girls at age 15 years (World Health Organization''s gold standard) reached 76% in 2015 but decreased to 69% in 2018, likely due to work overload in public immunization centres. In Denmark, doubts about safety and efficacy of the HPV vaccine generated a decline in coverage among girls age 12–17, from 80% in 2013 down to 37% in 2015, when remedial actions made it rise again. Insights from these two countries are shared to illustrate the importance of monitoring coverage in a digital vaccine registry and promptly reacting to misinformation about vaccination.
Abbreviations
- CC
- cervical cancer
- FVG
- Friuli Venezia Giulia
- HICs
- high‐income countries
- HPV
- human papillomavirus
- LMICs
- middle‐income countries
- WHO
- World Health Organization
9.
While two prophylactic HPV vaccines have been proven notably efficacious in clinical trials, the effectiveness of these vaccines at the population level remains to be evaluated. To lay the foundation for understanding the strengths and limitations of different endpoints for future effectiveness research, we present a comprehensive review of HPV-related clinical outcomes, including: (i) HPV type-specific positivity and persistence, (ii) Pap diagnoses (ASC-US, LSIL, and HSIL), (iii) histologic cervical cancer precursor lesions (i.e., CIN1, CIN2, and CIN3), (iv) invasive cervical cancer (ICC), (v) anogenital warts, (vi) recurrent respiratory papillomatosis (RRP), and (vii) other HPV-associated cancers (vulvar, vaginal, anal, penile, and oropharyngeal). While research on the vaccines’ effects on these HPV clinical outcomes in the general population is presently limited, numerous large trials will soon be completed, making a priori discussion of these potential outcomes especially urgent. Furthermore, population level systems to track HPV-associated clinical outcomes may need to be developed for HPV vaccine effectiveness evaluation. 相似文献
10.